98%
921
2 minutes
20
Background: Stroke is one of the most frequent causes of death and disability worldwide. It is accompanied by the impaired motor function of the upper extremities in over 69% of patients up to hemiplegia in the following 5 years in 56% of cases. This condition often is characterized by chronic poststroke pain, difficult to manage, further worsening quality of life. Poststroke pain occurs within 3-6 months. Robot-assisted neurorehabilitation using the Automatic Recovery Arm Motility Integrated System (ARAMIS) has proven efficacy in motor function recovery exploiting the movements and the strength of the unaffected arm. The rationale of the ROBOCOP (ROBOtic Care of Poststroke pain) randomized trial is the assessment of the impact of robot-assisted functional and motor recovery on the prevention of poststroke pain.
Methods: A total of 118 patients with hemiplegic arms due to stroke will be enrolled and randomly allocated with a 1:1 ratio to ARAMIS or conventional neurorehabilitation group. After a baseline screening at hospital discharge, ARAMIS or conventional rehabilitation will be performed for 8 weeks. The primary endpoint is the prevention of the development of poststroke pain and the secondary endpoints are prevention of spasticity and efficacy in clinical motor rehabilitation. The primary outcome measures consist in the visual analog scale and the doleur neuropatique 4 and the secondary outcome measures include: the Modified Ashworth Scale, the Resistance to Passive movement Scale; the Upper Extremity Subscale of the Fugl-Meyer Motor Assessment; the Action Research Arm Test; the Barthel Index for activities of daily living; and the magnetic resonance imaging (MRI) recovery-related parameters. After baseline, both primary and secondary outcome measures will be performed in the following time points: 1 month after stroke ( , half of the rehabilitation); 2 months after stroke ( , after rehabilitation); and 3 months ( ) and 6 months ( ) after stroke, critical for poststroke pain development.
Discussion: This is the first clinical trial investigating the efficacy of robot-assisted neurorehabilitation using ARAMIS on poststroke pain prevention. This study could remarkably improve the quality of life of stroke survivors.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894665 | PMC |
http://dx.doi.org/10.3389/fneur.2022.813282 | DOI Listing |
Cureus
September 2025
Rheumatology, University Hospitals Coventry & Warwickshire, Coventry, GBR.
Complex regional pain syndrome (CRPS) is a debilitating chronic pain condition that may develop after fractures, surgery, or soft tissue trauma. It is characterized by pain disproportionate to the initial injury, often accompanied by sensory, motor, autonomic, and trophic changes. Despite extensive research, pathophysiology remains unclear, and treatment approaches are varied, with inconsistent supporting evidence.
View Article and Find Full Text PDFNeurol Ther
September 2025
Department of Neurosurgery, The General Hospital of Western Theater Command, Chengdu, China.
Central post-stroke pain (CPSP) is an intractable neuropathic pain syndrome. Dual-target deep brain stimulation (DBS), which integrates sensory thalamic modulation and endogenous analgesic pathways, has emerged as a potential intervention; however, clinical evidence remains scarce. We report a 54-year-old woman who developed right-sided limb paresthesia progressing to persistent right hemibody pain following a left thalamic hemorrhage.
View Article and Find Full Text PDFJ Pain Res
August 2025
Department of Pain Management, The Affiliated Hospital, Southwest Medical University, Luzhou, People's Republic of China.
Background And Purpose: Central post-stroke pain (CPSP) is directly caused by cerebrovascular diseases that affect the central somatosensory system. It is a serious, chronic central neuropathic pain that responds poorly to first-line drugs. Oxymatrine (OMT), a monomer derived from the traditional Chinese medicine Ait.
View Article and Find Full Text PDFPain
May 2025
Department of Neurology, University of Iowa Carver College of Medicine, Iowa City, IA, United States.
Identifying lesion sites associated with central poststroke pain (CPSP) may facilitate targeted screening for early symptoms, possibly even paving the way for preventive measures and earlier treatment initiation. Here, we test the hypothesis that damage to a nociceptive pathway extending from the brainstem to the cerebral cortex, and including white matter tracts, is associated with CPSP. We investigated the lesion locations of 72 patients with CPSP relative to poststroke comparison subjects without pain (n = 123), divided into a discovery and independent validation data set.
View Article and Find Full Text PDFBrain Behav Immun
August 2025
Department of Anesthesiology, Hubei Key Laboratory of Geriatric Anesthesia and Perioperative Brain Health, and Wuhan Clinical Research Center for Geriatric Anesthesia, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China. Electronic add
Background: Central post-stroke pain (CPSP) is a chronic neuropathic pain syndrome that develops following cerebrovascular injury and currently lacks effective treatment options. Previous research from our group has found a significant number of apoptotic cells in the thalamus of CPSP rats, and in the nervous system, the failure to promptly clear apoptotic cell debris can activate microglia, triggering a persistent neuroinflammatory response that contributes to the onset and progression of CPSP. Microglia clear apoptotic cells in the central nervous system through efferocytosis, a process that reduces neuroinflammation and promotes the reprogramming of microglia toward the M2 phenotype, which is crucial for immune defense and repair mechanisms in the central nervous system.
View Article and Find Full Text PDF